SLNCF — Silence Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $906.79m
- $714.03m
- £25.38m
- 63
- 11
- 57
- 40
Annual cashflow statement for Silence Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.9 | -36 | -45.9 | -47.4 | -50.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.722 | 7.96 | 8.98 | 9.69 | 15.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 23.4 | 16.8 | 43.3 | -8.26 | -5.45 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1.73 | -10.8 | 6.81 | -45.5 | -39.4 |
| Capital Expenditures | -0.009 | -0.514 | -1.33 | -16.6 | -20.7 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -15 | 10.1 | 10 | 0.023 | 37.1 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -15 | 9.62 | 8.68 | -16.5 | 16.4 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.27 | 15.4 | 30.7 | 43 | 25.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -7.98 | 13.9 | 46.1 | -18.7 | -0.785 |